ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)
8.76
-0.34 (-3.74%)
Sep 10, 2026, 3:04 PM CST
SHE:300254 Revenue
ShanXi C&Y Pharmaceutical Group Co.,LTD. had revenue of 178.08M CNY in the quarter ending June 30, 2026, a decrease of -6.89%. This brings the company's revenue in the last twelve months to 849.67M, up 3.81% year-over-year. In the year 2025, ShanXi C&Y Pharmaceutical Group Co.,LTD. had annual revenue of 870.79M with 2.86% growth.
Revenue (ttm)
849.67M
Revenue Growth
+3.81%
P/S Ratio
2.74
Revenue / Employee
731.22K
Employees
1,162
Market Cap
2.33B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 870.79M | 24.18M | 2.86% |
| Dec 31, 2024 | 846.61M | 47.30M | 5.92% |
| Dec 31, 2023 | 799.31M | -29.69M | -3.58% |
| Jan 1, 2023 | 829.00M | -101.38M | -10.90% |
| Jan 1, 2022 | 930.37M | 82.30M | 9.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Shengda Bio-Pharm | 832.86M |
| Enwei Pharmaceutical | 826.13M |
| Hainan Huluwa Pharmaceutical Group | 634.04M |
| Chengdu huasun technology group Inc. , LTD. | 486.70M |
| Zhejiang Shapuaisi Pharmaceutical | 423.20M |
| Anhui Huangshan Capsule | 407.10M |
| Guhan Pharmaceutical Group | 329.41M |
| Qinghai Spring Medicinal Resources Technology | 303.67M |